Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle Fisher

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Plos Medicine|April 17, 2019
Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort studyAdam Penn-Nicholson, Thomas Hraha, Ethan G Thompson, et al.
Plos Medicine|July 19, 2019
Correction: Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort studyAdam Penn-Nicholson, Thomas Hraha, Ethan G Thompson, et al.
Nature Microbiology|April 24, 2024
Age and sex influence antibody profiles associated with tuberculosis progressionLeela R L Davies, Chuangqi Wang, Pia Steigler, et al.
Frontiers in Microbiology|July 13, 2019
Detection of Tuberculosis Recurrence, Diagnosis and Treatment Response by a Blood Transcriptomic Risk Signature in HIV-Infected Persons on Antiretroviral TherapyFatoumatta Darboe, Stanley Kimbung Mbandi, Kogieleum Naidoo, et al.
Ebiomedicine|March 18, 2025
Safety, reactogenicity, and immunogenicity of MTBVAC in infants: a phase 2a randomised, double-blind, dose-defining trial in a TB endemic settingMichele Tameris, Virginie Rozot, Claire Imbratta, et al.
The Lancet. Global Health|April 18, 2025
Live-attenuated Mycobacterium tuberculosis vaccine, MTBVAC, in adults with or without M tuberculosis sensitisation: a single-centre, phase 1b-2a, double-blind, dose-escalation, randomised controlled trialAngelique Kany Kany Luabeya, Virginie Rozot, Claire Imbratta, et al.
The Journal of Infectious Diseases|April 9, 2020
Peripheral Blood Mucosal-Associated Invariant T Cells in Tuberculosis Patients and Healthy Mycobacterium tuberculosis-Exposed ControlsSara Suliman, Anele Gela, Simon C Mendelsohn, et al.
Scientific Reports|May 27, 2020
RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment responseAdam Penn-Nicholson, Stanley Kimbung Mbandi, Ethan Thompson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 17, 2025
Mycobacterium tuberculosis-specific blood immune signatures distinguish sarcoidosis from tuberculosis diseaseLeila Y Chihab, Catherine Cheng, Hannah Hillman, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Plos Medicine|April 17, 2019
Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort studyAdam Penn-Nicholson, Thomas Hraha, Ethan G Thompson, et al.
Plos Medicine|July 19, 2019
Correction: Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort studyAdam Penn-Nicholson, Thomas Hraha, Ethan G Thompson, et al.
Nature Microbiology|April 24, 2024
Age and sex influence antibody profiles associated with tuberculosis progressionLeela R L Davies, Chuangqi Wang, Pia Steigler, et al.
Frontiers in Microbiology|July 13, 2019
Detection of Tuberculosis Recurrence, Diagnosis and Treatment Response by a Blood Transcriptomic Risk Signature in HIV-Infected Persons on Antiretroviral TherapyFatoumatta Darboe, Stanley Kimbung Mbandi, Kogieleum Naidoo, et al.
Ebiomedicine|March 18, 2025
Safety, reactogenicity, and immunogenicity of MTBVAC in infants: a phase 2a randomised, double-blind, dose-defining trial in a TB endemic settingMichele Tameris, Virginie Rozot, Claire Imbratta, et al.
The Lancet. Global Health|April 18, 2025
Live-attenuated Mycobacterium tuberculosis vaccine, MTBVAC, in adults with or without M tuberculosis sensitisation: a single-centre, phase 1b-2a, double-blind, dose-escalation, randomised controlled trialAngelique Kany Kany Luabeya, Virginie Rozot, Claire Imbratta, et al.
The Journal of Infectious Diseases|April 9, 2020
Peripheral Blood Mucosal-Associated Invariant T Cells in Tuberculosis Patients and Healthy Mycobacterium tuberculosis-Exposed ControlsSara Suliman, Anele Gela, Simon C Mendelsohn, et al.
Scientific Reports|May 27, 2020
RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment responseAdam Penn-Nicholson, Stanley Kimbung Mbandi, Ethan Thompson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 17, 2025
Mycobacterium tuberculosis-specific blood immune signatures distinguish sarcoidosis from tuberculosis diseaseLeila Y Chihab, Catherine Cheng, Hannah Hillman, et al.
Pageof 3